source Post navigation Novo Nordisk’s Semaglutide Cuts Death Risk in Diabetics with CKD in Phase III Trial – BioSpace Global Diabetes Drug Analysis Report 2024: A $107.02 Billion Market by 2032 Driven by Novo Nordisk, AstraZeneca … – GlobeNewswire